# A Clinical Study to Evaluate the Safety and Efficacy of OrienX010 in Unresectable Malignant Melanoma Patients

> **NCT04200040** · PHASE2 · UNKNOWN · sponsor: **OrienGene Biotechnology Ltd.** · enrollment: 165 (estimated)

## Conditions studied

- Melanoma (Skin)

## Interventions

- **BIOLOGICAL:** OrienX010 injection
- **DRUG:** Dacarbazine (DTIC)

## Key facts

- **NCT ID:** NCT04200040
- **Lead sponsor:** OrienGene Biotechnology Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-08-27
- **Primary completion:** 2022-12-27
- **Final completion:** 2022-12-27
- **Target enrollment:** 165 (ESTIMATED)
- **Last updated:** 2020-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04200040

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04200040, "A Clinical Study to Evaluate the Safety and Efficacy of OrienX010 in Unresectable Malignant Melanoma Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04200040. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*